Most anticancer drugs that enter clinical testing in children and adolescents fail to reach late-phase trials or earn pediatric regulatory approval, according to the authors of new research. Over a 15 ...
Adverse drug reactions (ADRs) represent a significant cause of morbidity and mortality in children, who face distinct pharmacological vulnerabilities due to unique physiological development. Current ...